ArticleAging2019
Elevated ceramides 18:0 and 24:1 with aging are associated with hip fracture risk through increased bone resorption.
Article in Aging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 25 citations in OpenAlex.
- Osteoprotegerin and receptor activator of NF-kappaB ligand as biomarkers for bone resorption-related disorders.World journal of experimental medicine · 2026Review
- Elevated Circulating Ceramides 18:0 and 24:1 as a Risk Factor for Sarcopenia: In Vitro, Animal, and Clinical Evidence.Journal of cachexia, sarcopenia and muscle · 2026Article
- Impact of sodium-glucose cotransporter-2 inhibitors on aging biomarkers and plasma ceramide levels in type 2 diabetes: beyond glycemic control.Annals of medicine · 2025Article
- Age- and sex-associated effects of C18 ceramide sphingolipids on osteoclastogenesis in experimental models of Gulf War Illness.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025Article
- Lipid metabolism in age-related musculoskeletal disorders: insights into sarcopenia and osteoporosis.BMC biology · 2025Review
- Elevated long-to-very-long-chain ceramide ratio correlates with disease severity in inflammatory bowel disease and primary sclerosing cholangitis.Scientific reports · 2025Article
- Serum phospholipids during aging: A comprehensive systematic review of cross-sectional and case-control studies.Health promotion perspectives · 2025Review
- Role of Canonical and Non-Canonical Sphingolipids and their Metabolic Enzymes in Bone Health.Current osteoporosis reports · 2025Review
- Profile of the Main Representatives of Sphingolipid Metabolism in the Maxillary and Mandibular Periosteum of Patients with Dentofacial Deformities After Osteosynthesis Using Titanium Implants.Journal of clinical medicine · 2025Article
- Advancements in the Optimization of Surgical Timing in Elderly Patients with Hip Fractures: A Narrative Review and Future Perspectives.Clinical interventions in aging · 2025Review
- Cancer cachexia: biomarkers and the influence of age.Molecular oncology · 2024Review
- Ying and Yang of Ceramide in the Vascular Endothelium.Arteriosclerosis, thrombosis, and vascular biology · 2024Review
- Sphingolipid-Induced Bone Regulation and Its Emerging Role in Dysfunction Due to Disease and Infection.International journal of molecular sciences · 2024Review
- Inhibition of acid sphingomyelinase by imipramine abolishes the synergy between metabolic syndrome and periodontitis on alveolar bone loss.Journal of periodontal research · 2022Article
- Influence of gestational diabetes mellitus on lipid signatures in breast milk and association with fetal physical development.Frontiers in nutrition · 2022Article
- Rethinking Fragility Fractures in Type 2 Diabetes: The Link between Hyperinsulinaemia and Osteofragilitas.Biomedicines · 2021Review
- Lumican Inhibits Osteoclastogenesis and Bone Resorption by Suppressing Akt Activity.International journal of molecular sciences · 2021Article
- The Role of Sphingolipid Metabolism in Bone Remodeling.Frontiers in cell and developmental biology · 2021Review
- miR-205 regulates bone turnover in elderly female patients with type 2 diabetes mellitus through targeted inhibition of Runx2.Experimental and therapeutic medicine · 2020Article
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We assessed whether circulating ceramides, which play a role in a number of degenerative changes with aging, significantly differed according to fragility hip fracture (HF) status. We also performed a human study using bone marrow (BM) aspirates, directly reflecting the bone microenvironment, in addition to
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.